Updated:
BioCorRx Inc.
BioCorRx Inc. develops naltrexone implants for addiction treatment. Lead candidate BICX104 targets opioid and alcohol use disorders.
BioCorRx Inc.
BioCorRx Inc. is a development-stage biopharmaceutical entity focused on treating addiction and substance use disorders. The company’s lead candidate, BICX104, is an implantable, once-monthly naltrexone formulation designed to improve compliance in patients with opioid or alcohol dependence (per SEC filings, 2023). It also markets UnCraveRX, a weight-loss supplement, but the core value driver is the addiction pipeline. Strategy centers on advancing BICX104 through Phase 1 clinical trials, with prior work completed in Spain and planned expansion into US-based studies. BioCorRx does not maintain a disclosed asset-class mix, deployment pace, or a roster of external portfolio companies. The firm operates from a single location, with no publicly known fund structures or co-investment vehicles. Team size is minimal, comprising a handful of named executives — CEO Lourdes Felix, CFO Ajay Grover, and Chief Medical Officer Dr. Steven McCarus — per SEC filings. No philanthropic or operating-company adjacencies are publicly recorded. The most recent operational event is the filing of a patent for BICX104 in April 2024 (per USPTO record). A structural differentiator is the firm’s reliance on a special-purpose vehicle, a 2017 licensing agreement with the University of Texas Health Science Center, which provided the naltrexone implant technology (per SEC filings). This single-source innovation model is rare among family offices and distinguishes BioCorRx as a shallow, asset-owning entity rather than a diversified investment office.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at BioCorRx?
CEO Lourdes Felix oversees corporate strategy and pipeline development. The company’s board includes six directors, some with pharmaceutical backgrounds (per SEC filings, 2023). No single-family-office structure or external allocator controls decision-making.
Does BioCorRx operate as a family office or a traditional drug developer?
BioCorRx is a publicly traded, development-stage biopharmaceutical company, not a family office. It issues shares and reports under the SEC. The firm has no disclosed family-office affiliation or wealth-management mandate.
What is the underlying wealth origin for BioCorRx?
BioCorRx does not manage external wealth. It raises capital through public equity offerings (per SEC filings, 2023). No family or individual benefactor is associated with the firm in a family-office capacity.
How does BioCorRx source its technology?
BioCorRx licensed its core naltrexone implant technology from the University of Texas Health Science Center in 2017 (per SEC filings). This single-source arrangement limits its pipeline breadth but provides a patented delivery mechanism for addiction treatment.
What investment stages does BioCorRx target?
BioCorRx operates as a development-stage firm, not an investor. It does not target investment stages, make direct deals, or participate in co-investments. It is a corporate entity advancing a single product through clinical trials.
Does BioCorRx maintain philanthropic structures?
BioCorRx has no publicly disclosed philanthropic foundations, trusts, or earmarked charitable vehicles. Its operations are purely for-profit (per SEC filings).
What regulatory environment affects BioCorRx?
BioCorRx must comply with FDA requirements for drug approval. Its BICX104 implant received Investigational New Drug clearance in the US in 2022 (per SEC filings), allowing Phase 1 trials.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: